BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-06-11 07:00 |
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN …
|
English | 252.5 KB | ||
| 2021-06-11 07:00 |
BERGENBIO PRESENTERER LOVENDE OPPDATERTE PRELIMINÆRE DATA FRA FASE-II STUDIE I …
|
Norwegian | 246.5 KB | ||
| 2021-06-11 07:00 |
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN …
|
English | 8.9 KB | ||
| 2021-06-11 07:00 |
BERGENBIO PRESENTERER LOVENDE OPPDATERTE PRELIMINÆRE DATA FRA FASE-II STUDIE I …
|
Norwegian | 9.3 KB | ||
| 2021-06-10 05:00 |
BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
|
English | 183.2 KB | ||
| 2021-06-10 05:00 |
BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
|
English | 5.8 KB | ||
| 2021-06-08 05:00 |
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 CO…
|
English | 54.5 KB | ||
| 2021-06-08 05:00 |
BERGENBIO MOTTAR FDA FAST TRACK DESIGNATION FOR BEMCENTINIB/ANTI-PD-(L)1 KOMBIN…
|
Norwegian | 222.2 KB | ||
| 2021-06-08 05:00 |
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 CO…
|
English | 8.1 KB | ||
| 2021-06-08 05:00 |
BERGENBIO MOTTAR FDA FAST TRACK DESIGNATION FOR BEMCENTINIB/ANTI-PD-(L)1 KOMBIN…
|
Norwegian | 8.3 KB | ||
| 2021-06-07 05:00 |
BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE …
|
English | 184.5 KB | ||
| 2021-06-07 05:00 |
BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE …
|
English | 6.9 KB | ||
| 2021-06-04 13:42 |
BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL…
|
English | 223.7 KB | ||
| 2021-06-04 13:42 |
BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL…
|
English | 8.7 KB | ||
| 2021-05-25 07:00 |
BERGENBIO TO PRESENT AT ABGSC SEMINAR
|
English | 200.8 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
